146 related articles for article (PubMed ID: 15883819)
1. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
3. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
5. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
[TBL] [Abstract][Full Text] [Related]
6. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
[TBL] [Abstract][Full Text] [Related]
11. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P; Kreuzer KA; Pursche S; Bonin Mv; Leopold T; Baskaynak G; Dörken B; Ehninger G; Ottmann O; Jenke A; Bornhäuser M; Schleyer E
Cancer Chemother Pharmacol; 2004 Apr; 53(4):313-23. PubMed ID: 14658008
[TBL] [Abstract][Full Text] [Related]
13. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
Boddy AV; Sludden J; Griffin MJ; Garner C; Kendrick J; Mistry P; Dutreix C; Newell DR; O'Brien SG
Clin Cancer Res; 2007 Jul; 13(14):4164-9. PubMed ID: 17634544
[TBL] [Abstract][Full Text] [Related]
15. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
16. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.
Oostendorp RL; Beijnen JH; Schellens JH; Tellingen Ov
Biomed Chromatogr; 2007 Jul; 21(7):747-54. PubMed ID: 17385801
[TBL] [Abstract][Full Text] [Related]
17. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
Peng B; Dutreix C; Mehring G; Hayes MJ; Ben-Am M; Seiberling M; Pokorny R; Capdeville R; Lloyd P
J Clin Pharmacol; 2004 Feb; 44(2):158-62. PubMed ID: 14747424
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
19. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
[TBL] [Abstract][Full Text] [Related]
20. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
Rochat B; Fayet A; Widmer N; Lahrichi SL; Pesse B; Décosterd LA; Biollaz J
J Mass Spectrom; 2008 Jun; 43(6):736-52. PubMed ID: 18286663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
